Cigna Group Affirms 2024 Earnings Guidance

Ticker: CI · Form: 8-K · Filed: 2024-09-03T00:00:00.000Z

Sentiment: neutral

Topics: guidance-affirmation, earnings, financial-outlook

TL;DR

Cigna Group confirms 2024 EPS $28.25-$29.05 and revenue $190B-$192B.

AI Summary

On September 3, 2024, The Cigna Group filed an 8-K to affirm its earnings guidance for the full year 2024. The company expects to achieve adjusted earnings per share (EPS) between $28.25 and $29.05, and adjusted revenue between $190 billion and $192 billion. This filing serves as an update and confirmation of previously issued financial outlook.

Why It Matters

This affirmation provides investors with continued confidence in Cigna Group's financial performance and outlook for the remainder of 2024.

Risk Assessment

Risk Level: low — The filing is a routine affirmation of previously provided guidance, indicating no new material negative information.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose is to affirm The Cigna Group's previously issued earnings guidance for the full year 2024.

What is the projected range for The Cigna Group's adjusted earnings per share (EPS) for 2024?

The projected range for adjusted EPS is between $28.25 and $29.05.

What is the projected range for The Cigna Group's adjusted revenue for 2024?

The projected range for adjusted revenue is between $190 billion and $192 billion.

On what date was this 8-K filing made?

The filing was made on September 3, 2024.

Does this filing indicate any changes to the previously announced guidance?

No, the filing serves as an affirmation, indicating the company is confirming its existing guidance and not announcing changes.

From the Filing

0000950159-24-000274.txt : 20240903 0000950159-24-000274.hdr.sgml : 20240903 20240903061513 ACCESSION NUMBER: 0000950159-24-000274 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240903 ITEM INFORMATION: Regulation FD Disclosure FILED AS OF DATE: 20240903 DATE AS OF CHANGE: 20240903 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cigna Group CENTRAL INDEX KEY: 0001739940 STANDARD INDUSTRIAL CLASSIFICATION: HOSPITAL & MEDICAL SERVICE PLANS [6324] ORGANIZATION NAME: 02 Finance IRS NUMBER: 824991898 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38769 FILM NUMBER: 241271818 BUSINESS ADDRESS: STREET 1: 900 COTTAGE GROVE ROAD CITY: BLOOMFIELD STATE: CT ZIP: 06002 BUSINESS PHONE: 8602266000 MAIL ADDRESS: STREET 1: 900 COTTAGE GROVE ROAD CITY: BLOOMFIELD STATE: CT ZIP: 06002 FORMER COMPANY: FORMER CONFORMED NAME: Cigna Corp DATE OF NAME CHANGE: 20181221 FORMER COMPANY: FORMER CONFORMED NAME: Halfmoon Parent, Inc. DATE OF NAME CHANGE: 20180508 8-K 1 cigna8k.htm THE CIGNA GROUP FORM 8-K The Cigna Group Form 8-K Earnings Affirmation false 0001739940 0001739940 2024-09-03 2024-09-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares     UNITED STATES   SECURITIES AND EXCHANGE COMMISSION   Washington, D.C. 20549   FORM 8-K     CURRENT REPORT   Pursuant to Section 13 or 15(d) of the   Securities Exchange Act of 1934   Date of Report (Date of earliest event reported) September 3, 2024   The Cigna Group   (Exact name of registrant as specified in its charter)   Delaware (State or other jurisdiction of  incorporation) 001-38769 (Commission File Number) 82-4991898 (IRS Employer Identification No.)     900 Cottage Grove Road Bloomfield , Connecticut 06002   (Address of principal executive offices) (Zip Code)   Registrant’s telephone number, including area code:   ( 860 ) 226-6000   Not Applicable   (Former name or former address, if changed since last report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, Par Value $0.01 CI New York Stock Exchange , Inc.   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).   Emerging growth company ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐               Item 7.01 Regulation FD Disclosure.   2024 Outlook Affirmation   The Cigna Group (the “Company” or “our”) officials expect to participate in meetings with investors and analysts over the next several weeks. During these meetings, The Cigna Group officials expect to reaffirm projected full year 2024 consolidated adjusted income from operations on a per share basis of at least $28.40 per share. The Cigna Group previously discussed its full year

View on Read The Filing